ClinicalTrials.gg

Program

IRL757

A development code.

Its studies are mostly in Parkinson Disease, led by Integrative Research Laboratories AB.

Furthest: phase 2, since Feb 17, 20263 company-led studies, 1 open or runningNext primary completion: May 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Integrative Research Laboratories AB31 open or runningphase 2since Feb 17, 2026May 29, 2024May 2027phase 2 · NCT07461220

Also a collaborator on its studies: Otsuka.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 29, 2024First study: phase 1 study in Not DeterminedFirst studyNCT06493045 · 82 enrolled · Sweden
  2. Oct 22, 2024Phase 1 study in LethargyNCT06699628 · 12 enrolled · Sweden
  3. Feb 17, 2026Phase 2 study in Parkinson DiseasePhase 2 reachedNCT07461220 · 75 planned · Bulgaria, Germany, Poland and more

Ahead

  1. May 2027Primary completion: phase 2 study in Parkinson DiseaseNCT07461220

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07461220Parkinson Disease · Bulgaria, Germany, Poland and more2RecruitingMay 202775
NCT06699628Lethargy · Sweden1CompletedNov 11, 202412
NCT06493045Not Determined · Sweden1CompletedFeb 7, 202582

How it is read

Names in the registry

  • “IRL757”, 3 entries

Codes read as this program: IRL757.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.